The therapeutic role of Cannabidiol in mental health : a systematic review Rabia Khan, Sadiq Naveed, Nadeem Mian, Ania Fida, Muhammad Abdur Raafey and Kapil Kiran Aedma Journal of Cannabis Research, 2020, 2, 2 doi : 10.1186/s42238-019-0012-y Abstract Background : The therapeutic application of cannabidiol (CBD) is gaining interest due to expanding evidence for its use. Objective : To summarize the clinical outcomes, study designs and limitations for the use of CBD and nabiximols (whole plant extract from Cannabis sativa L. that has been purified into 1:1 ratio of CBD and delta-9- tetrahydrocannabinol) in the treatment of psychiatric disorders. Materials and method : A systematic review was [...]
Lire la suiteLongitudinal Changes in Cognition in Young Adult Cannabis Users Mary Becker, Paul F. Collins, Ashley Schultz, Snežana Urošević, Brittany Schmaling, and Monica Luciana The Journal of Clinical and Experimental Neuropsychology, 2018, 40, (6), 529–543. doi : 10.1080/13803395.2017.1385729 Abstract Introduction : Adolescent cannabis use (CU) is associated with impaired attention, executive function, and verbal learning/memory. These associations are generally observed in cross-sectional studies. Longitudinal studies of cannabis users are lacking. Method : The present study examines associations between CU and cognition over time in chronic daily adolescent-onset CUs, as compared to non-using controls. Both groups completed a neuropsychological battery at study intake and again two years later. Results [...]
Lire la suiteLe cannabidiol, un agent thérapeutique prometteur ? Benjamin Rolland , Mathieu Chappuy, Patrizia Carrieri SWAPS, 3e et 4e trimestre 2019, n° 92-93, , 5-6. Deuxième cannabinoïde le plus étudié après le THC, sans effet psychoactif, le cannabidiol dispose de propriétés thérapeutiques intéressantes, notamment en psychiatrie. Le point sur les recherches La grande famille des cannabinoïdes Les cannabinoïdes sont un ensemble de substances capables d’activer les récepteurs du même nom (« récepteurs cannabinoïdes »). Il existe deux grandes familles de récepteurs cannabinoïdes, CB1 et CB2. Dans le système nerveux central, c’est surtout CB1 qui est exprimé, alors que CB2 est principalement présent dans le système immunitaire. [...]
Lire la suiteA novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol : Δ9-Tetrahydrocannabiphorol Cinzia Citti, Pasquale Linciano, Fabiana Russo, Livio Luongo, Monica Iannotta, Sabatino Maione, Aldo Laganà, Anna Laura Capriotti, Flavio Forni, Maria Angela Vandelli, Giuseppe Gigli & Giuseppe Cannazza Scientific Reports | (2019) 9:20335 | www.nature.com/scientificreports Doi : 10.1038/s41598-019-56785-1 (-)-Trans-Δ9-tetrahydrocannabinol (Δ9-THC) is the main compound responsible for the intoxicant activity of Cannabis sativa L. The length of the side alkyl chain influences the biological activity of this cannabinoid. In particular, synthetic analogues of Δ9-THC with a longer side chain have shown cannabimimetic properties far higher than Δ9-THC [...]
Lire la suiteIsolation and Pharmacological Evaluation of Minor Cannabinoids from High-Potency Cannabis sativa Mohamed M. Radwan, Mahmoud A. ElSohly, Abir T. El-Alfy, Safwat A. Ahmed, Desmond Slade, Afeef S. Husni, Susan P. Manly, Lisa Wilson, Suzanne Seale, Stephen J. Cutler, and Samir A. Ross Journal of Natural Products, 2015 June 26, 78, (6), 1271–1276. doi : 10.1021/acs.jnatprod.5b00065 Abstract Seven new naturally occurring hydroxylated cannabinoids (1–7), along with the known cannabiripsol (8), have been isolated from the aerial parts of high-potency Cannabis sativa. The structures of the new compounds were determined by 1D and 2D NMR spectroscopic analysis, GC-MS, and HRESIMS as 8α hydroxy-Δ9-tetrahydrocannabinol (1), 8β-hydroxy-Δ9-tetrahydrocannabinol (2), 10α-hydroxy-Δ8 [...]
Lire la suiteInvestigation of Sex-Dependent Effects of Cannabis in Daily Cannabis Smokers Ziva D. Cooper and Margaret Haney Drug & Alcohol Dependence, 2014 March 1, 136, 85–91. doi :10.1016/j.drugalcdep.2013.12.013 Abstract Background—Women exhibit an accelerated progression from first cannabis use to cannabis use disorder (CUD) and show pronounced negative clinical issues related to CUD relative to men. Whether sex-dependent differences in cannabis’ direct effects contribute to the heightened risk in women is unknown. This analysis directly compared cannabis’ abuse-related subjective effects in men and women matched for current cannabis use. Methods—Data from four double-blind, within-subject studies measuring the effects of active cannabis (3.27–5.50% THC, depending on study) relative to [...]
Lire la suiteLe THCP : un nouveau cannabinoïde 33 fois plus fort que le THC Blog-cannabis.fr, 31 décembre 2019 https://www.blog-cannabis.fr/2019/12/31/thcp-nouveau-cannabinoide/ Un nouveau phytocannabinoïde isolé du Cannabis sativa L avec une activité cannabimimétique 30 fois supérieure au THC a été détecté dans le cannabis Le cannabinoïde végétal Tetrahydrocannabiphorol ( THCP ) le plus puissant au monde a récemment été découvert dans une étude en Italie. Il est presque identique dans sa structure au THC mais est 33 fois plus fort que lui, ainsi que du CBDP, le dérivé correspondant du CBD. La recherche pourrait permettre de développer de futures souches de THCP beaucoup plus puissantes. Jusqu’à présent, près de 150 [...]
Lire la suiteThe effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial Steliana Yanakieva, Naya Polychroni, Neiloufar Family, Luke T. J. Williams, David P. Luke, Devin B. Terhune Psychopharmacology, 2018 Doi : 10.1007/s00213-018-5119-x Abstract Rationale : Previous research demonstrating that lysergic acid diethylamide (LSD) produces alterations in time perception has implications for its impact on conscious states and a range of psychological functions that necessitate precise interval timing. However, interpretation of this research is hindered by methodological limitations and an inability to dissociate direct neurochemical effects on interval timing from indirect effects attributable to altered states of consciousness. Methods : We conducted a randomised, double-blind, [...]
Lire la suiteA systematic study of microdosing psychedelics RESEARCH ARTICLE Vince Polito, Richard J. Stevenson PLoS ONE, 2019, 14, (2), e0211023. Doi : 10.1371/journal.pone.0211023 Abstract The phenomenon of ‘microdosing’, that is, regular ingestion of very small quantities of psychedelic substances, has seen a rapid explosion of popularity in recent years. Individuals who microdose report minimal acute effects from these substances yet claim a range of long-term general health and wellbeing benefits. There have been no published empirical studies of microdosing and the current legal and bureaucratic climate makes direct empirical investigation of the effects of psychedelics difficult. In Study One we conducted a systematic, observational investigation of individuals [...]
Lire la suiteAccounting for Microdosing Classic Psychedelics Blake Beaton, Heith Copes, Megan Webb, Andy Hochstetler, and Peter S. Hendricks Journal of Drug Issues, 2019, 1–12 Doi : 10.1177/0022042619871008 Abstract Microdosing classic psychedelics (e.g., LSD [lysergic acid diethylamide] and psilocybin) is the practice of taking small amounts of these substances to bring about various positive life changes. Little is known about the subjective experiences and perceptions of those who engage in the practice. Accordingly, we use the sociology of accounts as a theoretical framework to explore the ways that those who microdose excuse or justify their practice. Using data from semistructured interviews with 30 people who had microdosed, [...]
Lire la suite